DE602004031642D1 - Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine - Google Patents
Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteineInfo
- Publication number
- DE602004031642D1 DE602004031642D1 DE602004031642T DE602004031642T DE602004031642D1 DE 602004031642 D1 DE602004031642 D1 DE 602004031642D1 DE 602004031642 T DE602004031642 T DE 602004031642T DE 602004031642 T DE602004031642 T DE 602004031642T DE 602004031642 D1 DE602004031642 D1 DE 602004031642D1
- Authority
- DE
- Germany
- Prior art keywords
- protein variant
- biological response
- mutines
- effectiveness
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 238000003259 recombinant expression Methods 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030051846A KR100632985B1 (ko) | 2003-07-26 | 2003-07-26 | 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들 |
| PCT/KR2004/001246 WO2005010043A1 (en) | 2003-07-26 | 2004-05-27 | A method of improving efficacy of biological response-modifying proteins and the exemplary muteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004031642D1 true DE602004031642D1 (de) | 2011-04-14 |
Family
ID=36284112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004031642T Expired - Lifetime DE602004031642D1 (de) | 2003-07-26 | 2004-05-27 | Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7569361B2 (de) |
| EP (1) | EP1668030B1 (de) |
| JP (1) | JP4747238B2 (de) |
| KR (1) | KR100632985B1 (de) |
| CN (2) | CN101384620B (de) |
| AT (1) | ATE500266T1 (de) |
| AU (1) | AU2004259314B2 (de) |
| BR (1) | BRPI0412607A (de) |
| CA (1) | CA2528458A1 (de) |
| DE (1) | DE602004031642D1 (de) |
| ES (1) | ES2362453T3 (de) |
| RU (1) | RU2432360C2 (de) |
| WO (1) | WO2005010043A1 (de) |
| ZA (1) | ZA200600502B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| KR20080019606A (ko) * | 2005-05-04 | 2008-03-04 | 나우틸루스 바이오텍 | 변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법 |
| JP2010510794A (ja) | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| US8592374B2 (en) | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
| EP2009103A1 (de) | 2007-03-16 | 2008-12-31 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neurotrophische Peptide |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| KR101510743B1 (ko) | 2013-07-23 | 2015-04-10 | (주)케어젠 | 파골 세포 분화 억제용 펩타이드 및 이의 용도 |
| US10052343B1 (en) * | 2017-02-03 | 2018-08-21 | Gene Signal International Sa | Sterile formulation comprising a stable phosphorothioate oligonucleotide |
| EP3596108A4 (de) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | Gezielte immuntoleranz |
| KR101947342B1 (ko) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | Gm-csf 반감기를 증가시키는 방법 |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | ＭＡｄＣＡＭ標的化免疫寛容 |
| CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
| WO2024099445A1 (zh) * | 2022-11-10 | 2024-05-16 | 康立泰生物医药(青岛)有限公司 | 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3923963A1 (de) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| WO1999057147A1 (fr) * | 1998-04-30 | 1999-11-11 | Kirin Brewery Company, Limited | Mutants de la thrombopoietine humaine |
| DE60332556D1 (de) * | 2002-05-01 | 2010-06-24 | Danisco Us Inc | Cytokine und cytokinrezeptoren mit reduzierter immunogenität |
-
2003
- 2003-07-26 KR KR1020030051846A patent/KR100632985B1/ko not_active IP Right Cessation
-
2004
- 2004-05-27 DE DE602004031642T patent/DE602004031642D1/de not_active Expired - Lifetime
- 2004-05-27 CN CN2004800216797A patent/CN101384620B/zh not_active Expired - Fee Related
- 2004-05-27 AT AT04735139T patent/ATE500266T1/de not_active IP Right Cessation
- 2004-05-27 BR BRPI0412607-6A patent/BRPI0412607A/pt not_active IP Right Cessation
- 2004-05-27 WO PCT/KR2004/001246 patent/WO2005010043A1/en active Search and Examination
- 2004-05-27 JP JP2006521777A patent/JP4747238B2/ja not_active Expired - Fee Related
- 2004-05-27 EP EP04735139A patent/EP1668030B1/de not_active Expired - Lifetime
- 2004-05-27 AU AU2004259314A patent/AU2004259314B2/en not_active Ceased
- 2004-05-27 CN CN2011101763552A patent/CN102286090A/zh active Pending
- 2004-05-27 ES ES04735139T patent/ES2362453T3/es not_active Expired - Lifetime
- 2004-05-27 US US10/519,390 patent/US7569361B2/en not_active Expired - Lifetime
- 2004-05-27 RU RU2006102846/10A patent/RU2432360C2/ru not_active Application Discontinuation
- 2004-05-27 CA CA002528458A patent/CA2528458A1/en not_active Abandoned
-
2006
- 2006-01-18 ZA ZA200600502A patent/ZA200600502B/en unknown
-
2009
- 2009-07-08 US US12/499,710 patent/US20100041586A1/en not_active Abandoned
-
2012
- 2012-04-02 US US13/437,701 patent/US20130089513A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0412607A (pt) | 2007-07-03 |
| AU2004259314B2 (en) | 2006-12-07 |
| ES2362453T3 (es) | 2011-07-05 |
| WO2005010043A1 (en) | 2005-02-03 |
| RU2006102846A (ru) | 2007-09-10 |
| JP2007524403A (ja) | 2007-08-30 |
| AU2004259314A1 (en) | 2005-02-03 |
| US20060008872A1 (en) | 2006-01-12 |
| US20130089513A1 (en) | 2013-04-11 |
| CN101384620A (zh) | 2009-03-11 |
| ZA200600502B (en) | 2007-02-28 |
| EP1668030A1 (de) | 2006-06-14 |
| ATE500266T1 (de) | 2011-03-15 |
| CN101384620B (zh) | 2011-08-17 |
| JP4747238B2 (ja) | 2011-08-17 |
| KR100632985B1 (ko) | 2006-10-11 |
| RU2432360C2 (ru) | 2011-10-27 |
| US7569361B2 (en) | 2009-08-04 |
| US20100041586A1 (en) | 2010-02-18 |
| EP1668030A4 (de) | 2006-06-14 |
| CN102286090A (zh) | 2011-12-21 |
| CA2528458A1 (en) | 2005-02-03 |
| KR20050013024A (ko) | 2005-02-02 |
| EP1668030B1 (de) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004031642D1 (de) | Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine | |
| MXPA05014215A (es) | Mapeo de genoma de elementos funcionales de adn y proteinas celulares. | |
| WO2006014349A3 (en) | Method of producing fully carbamylated erythropoietin | |
| DE60125381D1 (de) | Zusammensetzungen und verfahren mit analogen von g-csf | |
| ATE269402T1 (de) | Ikk-beta proteine, nukleinsäuren und verfahren | |
| EA021222B8 (ru) | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| MX2007003906A (es) | Metodos y composiciones para mejorar la produccion de proteinas recombinantes. | |
| DE69934242D1 (de) | Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen | |
| ATE357518T1 (de) | Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums | |
| ATE477272T1 (de) | Verwendung von stefin a als gerüstprotein | |
| DE69808743T2 (de) | Netrinrezeptoren | |
| Białkowska et al. | Extremophilic proteases as novel and efficient tools in short peptide synthesis | |
| CY1109631T1 (el) | Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ | |
| Martina et al. | Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor | |
| ATE455792T1 (de) | Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon | |
| ATE277171T1 (de) | Ikk-alpha proteine, nukleinsäuren und verfahren | |
| WO2007013358A3 (en) | Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent | |
| DE60319369D1 (de) | Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis | |
| ATE464320T1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| ATE532863T1 (de) | Verfahren zur anzucht von myokardzellen | |
| AU2001289034A1 (en) | Novel pdes and uses thereof | |
| ATE451457T1 (de) | Verfahren zur dipeptidherstellung | |
| Antonyan et al. | Proline-rich cytokine from neurosecretory granules: A new natural substrate for dipeptidyl peptidase IV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R097 | No opposition filed against granted patent, or epo opposition proceedings concluded without decision |
Ref document number: 1668030 Country of ref document: EP Effective date: 20111205 |
|
| R082 | Change of representative |
Ref document number: 1668030 Country of ref document: EP Representative=s name: TBK, 80336 MUENCHEN, DE |